Automated manufacturing of CAR NK cells [WEBINAR]

Learn about the current status of CAR engineered NK cells as an adoptive, cell-based immunotherapy, alongside the strategies developed for CAR NK cell generation.
Find more Miltenyi Biotec webinars at www.miltenyibiotec.com/resour...
With recent advances in immuno-oncology research, CAR NK cells have been highlighted as a promising approach for a cell-based immunotherapy. The critical role of immune cells in cancer therapy has been validated, and adoptive cell therapies are more frequently a treatment of choice. With increased amounts of clinical research taking place, we will review the current strategies of CAR NK cell generation.
Finally, we will observe Miltenyi Biotec’s solutions how we can introduce the new CliniMACS Prodigy Platform, a unique platform that allows the generation of gene-modified CAR NK cells in a standardized and fully automated fashion.
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries - all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

[@user-bc9kk3kb8u]

The video content is so excellent, congratulations

[@Miltenyi_Biotec]

Thank you very much!

[@richhogg8074]

I would be interested to know for how long CAR transgene expression is maintained in primary CAR NK cells after two weeks in culture

[@Miltenyi_Biotec]

In minute 22 of the webinar you can see that at day 15 50% of the NKs are still transduced. We also have a new webinar if you are interested. The title of the webinar is "Simplifying GMP CAR T and CAR NK cell therapy manufacturing processes". You can find it on our webpage www.miltenyibiotec.com/resources/video-library.html#/currentChannelId=62970/currentVideoId=-w4jMLX1bbz7TMJFUjgw-7 or on KZbin kzbin.info/www/bejne/hYXLg4F6lMuBiMU . In this webinar, you can see that after 14 days even 60% of the NK cells still express the CAR. You find this data in minute 13.